Low mother-to-child HIV transmission rate but high loss-to-follow-up among mothers and babies in Mandalay, Myanmar; a cohort study

Khine Wut Yee Kyaw¹ *, Myo Minn Oo¹ ☯, Nang Thu Thu Kyaw¹ ☯, Khaing Hnin Phyo²‡, Thet Ko Aung²‡, Theingi Mya³‡, Nilar Aung⁴‡, Htun Nyunt Oo⁵‡, Petros Isaakidis⁶*

¹ Department of Operational Research, International Union Against Tuberculosis and Lung Disease (The Union), Mandalay, Myanmar, ² HIV unit, International Union Against Tuberculosis and Lung Disease (The Union), Mandalay, Myanmar, ³ Department of Obstetrics and Gynecology, Central Women Hospital, Mandalay, Myanmar, ⁴ Neonatology unit, Central Women Hospital, Mandalay, Myanmar, ⁵ National AIDS Program, Department of Public Health, Ministry of Health and Sports, Nay Pyi Taw, Myanmar, ⁶ Department of Operational Research, Médecins Sans Frontières (MSF) / Doctors Without Borders, Mumbai, India

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.

*dr.khinewutyeekyaw2015@gmail.com

Abstract

Introduction

Loss-to-follow-up (LTFU) throughout the Prevention of Mother-To-Child Transmission (PMTCT) cascade remains one of the major threats to the success of PMTCT programs. In this study, we aimed to determine the mother-to-child transmission rate in a programmatic setting and to determine factors associated with LTFU among enrolled mothers and unfavorable outcomes among HIV-exposed babies which includes being HIV positive, death and LTFU.

Methods

A retrospective cohort study reviewing routinely collected data in an Integrated HIV care program, Mandalay, Myanmar in June 2016. LTFU means mother/infant missing appointed visit for more than three months.

Results

Of 678 pregnant women enrolled in PMTCT program between March 2011 and June 2014, one stillbirth and 607 live births were recorded in this cohort. Of 457 HIV-exposed babies with HIV-test recorded at the end of the intervention, nine (2%) were HIV-positive. Pregnant women’s and exposed-babies’ LTFU rate was 7 per 1000 person-years, and 10 per 1000 person-years respectively. PMTCT option B protocol was found to be significantly associated with maternal LTFU [adjusted Hazard Ratio (aHR) 95% CI: 3.52 (1.38–8.96)] when compare to mothers receiving option B+/lifelong antiretroviral therapy (ART). Weight <2.5 Kg at enrolment, receiving mixed-feeding, vaginal delivery and option B PMTCT protocol were significantly
associated with unfavorable outcomes among exposed babies \([\text{aHR(95\% CI)}: 5.40 \text{ (1.66–17.53)}, 5.91\text{ (1.68–20.84)}, 2.27 \text{ (1.22–4.22)} \text{ and } 2.33 \text{ (1.16–4.69)} \text{ respectively}].\)

**Conclusion**

Mother-to-child HIV transmission rate in this public hospital-based program was lower than the 5% national target, which indicates a successful PMTCT intervention. However, a high proportion of HIV-infected mothers and exposed babies LTFU was recorded. Lifelong ART provision to HIV-positive pregnant women was shown to reduce exposed babies' LTFU, death and transmission rate (unfavorable outcomes) in this setting. Lessons learned from this program could be used to inform policy and practice in the country, while the programmatic challenge of LTFU should be urgently addressed.

**Introduction**

Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) remains a major health problem worldwide even though the rate of transmission globally fell from 26% in 2009 to 16% in 2013 and 10% in 2015\[1\]. The transmission can happen during pregnancy, delivery and breastfeeding. It depends upon different factors including acute HIV infection in mothers, high maternal viral load, low CD4-cell counts, vaginal delivery, prolonged rupture of fetal membranes, breastfeeding, no antiretroviral therapy (ART) or short duration of ART before delivery and poor adherence to treatment. With a comprehensive interventions the risk of MTCT can be reduced to less than 5% (or even lower) in breastfeeding populations from a background risk of 35%, and to less than 2% in non-breastfeeding populations from a background risk of 25\%\[2–9\]. The annual number of new infection among children was reduced globally by 56% since 2010 and 70% since 2000 by improvement of PMTCT intervention.[1]

In 2013, 54% of pregnant women in low and middle-income countries did not receive routine HIV testing during antenatal care (ANC), which is a key step to accessing HIV prevention, treatment and care\[10\]. In 2015, 300,000 women did not receive ART or antiretroviral (ARV) prophylaxis to prevent MTCT. There is also high rate of treatment drop out in women who are pregnant and breastfeeding\[1\]. Globally, WHO and UNICEF projected that 1.9 million of children will acquire HIV infection in 2020\[11\].

In Myanmar, HIV prevalence in the adult population aged 15 years and older was estimated at 0.54% in 2014; it has considerably declined from 0.94% in 2000\[12,13\]. The HIV prevalence among pregnant women attending ANC was stable at less than 1% from 2011 to 2013\[13\]. At the end of 2013, about 3,000 women received PMTCT services, and nearly 90% of them were put on ART or ARV prophylaxis\[14\]. Myanmar has set the target in the National Strategic Plan to reduce the transmission rate to <5% by 2020 and to eliminate mother to child transmission of HIV by 2025.\[15\]

The PMTCT program in Myanmar is routinely monitored and evaluated however there has been no in-depth analysis of outcomes and factors associated with successful prevention, neither has been documented on lessons learned that could inform policy and practice.

The aim of this study was to determine the mother-to-child transmission rate among HIV-infected mothers and their exposed babies enrolled in the Mandalay Central Women Hospital PMTCT program between March 2011 and June 2014 and to investigate the factors associated with LTFU among enrolled mothers as well as factors associated with unfavorable outcomes among HIV-exposed babies.
Methods

Ethics approval

Permission for the study was obtained from National AIDS Program, Myanmar. Ethics approval was obtained from the Ethics Review Committee at Department of Medical Research, Yangon, Myanmar and the International Union Against Tuberculosis and Lung Disease (The Union) Ethics Advisory Group, Paris, France.

Study design

This was a retrospective cohort study using routinely collected data on PMTCT of an Integrated HIV Care (IHC) Program in Myanmar.

Setting

Myanmar is Southeast Asian country bordering India, Bangladesh, China, Laos and Thailand. The population of Myanmar was 53,259,000 in 2013 with 33% of the population living in urban areas.[16] About 6 million people live in Mandalay Region which is located in the center of the country. The Central Women Hospital in Mandalay is the largest facility offering comprehensive PMTCT services in the region. Minority of HIV-infected mothers from outside Mandalay Region were also enrolled in this PMTCT program.

PMTCT program description. Since 2011, The Union has been implementing PMTCT services in Central Women Hospital in Mandalay as a PMTCT clinic under IHC program, in collaboration with the National AIDS Program (NAP) and public hospitals and clinics under the Ministry of Health and Sports (MoHS). The PMTCT clinic enrolled HIV-infected pregnant women as well as post-partum women along with their exposed babies mainly delivered at CWH also other public hospitals and private clinic, and provided comprehensive PMTCT services. This integrated PMTCT care is delivered by obstetricians and pediatricians from CWH and physicians from Mandalay General Hospital as well as medical officers employed by the Union. Three counselling sessions on adherence to ART and regular follow up are offered to PMTCT women (1st session- at enrolment visit, 2nd during the blood collection day, and 3rd at a clinic appointed day) by peer counsellors and medical social workers from the hospital. The program collaborates with an extensive PLHIV network which provides comprehensive counselling services and LTFU tracing. The Union supports formula feeding to exposed babies until the 9th month of age and provides counselling and demonstration on formula feeding preparation in collaboration with the medical saffs from the hospital. Last, all enrolled mothers and babies are followed at the CWH PMTCT clinic until 18th month post-partum or until the child HIV status have been confirmed. Early infant diagnosis (EID) is also provided to HIV exposed infants.

HIV-infected pregnant women who were eligible for treatment were offered antiretroviral therapy (ART) for life if their CD4-counts is lower than cutoff point (CD4-count cutoff was 350 cells/mm³ before 2015 and 500 cells/mm³ after 2015)[3].Women with CD4-count higher than above cutoff point who did not need treatment for their own health were given antiretroviral (ARV) prophylaxis as per the following PMTCT protocols;

1. PMTCT option A (prior to 2013): women received AZT only
2. PMTCT option B (from 2011 to 2014): women received triple ART, during pregnancy, delivery and discontinued one week after breast feeding was stopped
3. PMTCT option B+ (2014 to date): women received triple ART during pregnancy, delivery and continued for life[2,17].
At enrollment, every mother and child are given a unique registration code. Baseline demographic characteristics along with history of pregnancy and delivery are collected and CD4-count for the mother is tested. After delivery, mother and infant are followed-up until 18 months post-partum. The follow-up visit frequency varied depending upon the attending physician, feeding practices, the health status of the mother and the infant and distance of patients’ resident. In every follow-up visit, mothers are asked to bring along their infants. Infants receive HIV virological testing (DNA/RNA PCR essay) at the age of 4–6 weeks and 9 months, and are tested for HIV serology by using rapid tests (Determine HIV-1/2) at the age of 9 and 18 months. The indeterminate results at 9 months are confirmed with DNA/RNA assay between 9 and 18 months of age. HIV-positive infants were transferred out to Pediatric IHC clinic for ART initiation of ART and continuation of care. Table 1 shows the programmatic definitions used in this study.

**Patient population**

HIV-infected mothers and their exposed infants enrolled in the PMTCT program and received PMTCT intervention in Central Women Hospital, Mandalay, Myanmar between March 2011 and June 2014.

**Sources of data, data variables**

In every visit at the PMTCT clinic, medical doctors filled out the standardized PMTCT visit forms, and trained data staffs transcribed the paper-based data into the electronic database of IHC program after each clinic session.

Collected variables included: PMTCT protocol, CD4-count before delivery, baseline WHO staging, mode of delivery, place of delivery, pregnancy outcomes, employment status and mother literacy status, sex of exposed infants, infant weight at enrolment, and mode of feeding.

**Statistical analysis**

Data were extracted from the electronic database of the IHC program and imported into STATA version 14.2 (College Station, TX). Data were anonymized and de-identified prior to analysis.

The number and proportion of mother LTFU, HIV transmission and unfavorable outcome of exposed babies (defined as HIV-positive, death and loss to follow-up) were calculated. Rate of LTFU among mothers and of unfavorable outcomes among exposed babies were calculated with censoring on 30th June 2016 for all exposed babies to have follow-up period up to 18 months of age. Cox proportional hazards models were used to determine the factors associated

| Table 1. Programmatic definitions. |
|------------------------------------|
| HIV-exposed infant                 | An infant who is born to an HIV-infected mother until HIV diagnosis is made. |
| Mother to child transmission of HIV (HIV positive) | an event of an infant who tested positive by DNA/RNA PCR test at 6th week of age or confirmed by DNA/RNA PCR test at 9th month of age or HIV antibody test at 18th month of age. |
| Regular follow up                  | mother/infant is alive and in care by the date of analysis |
| Lost-to-follow-up (LTFU)           | mother/infant missing appointed visit for more than three months |
| Death                              | mother/infant death, regardless cause of death |
| Transfer out                       | mother/infant transfer out to other IHC clinic |

https://doi.org/10.1371/journal.pone.0184426.t001
with mothers’ and exposed babies’ outcomes. P-value <0.05 was regarded as significant. A set of a priori variables based on knowledge from previous literatures such as PMTCT protocol, CD4 before delivery and mode of delivery were included as covariate in multivariable analysis to find the association with LTFU outcome of HIV-infected mothers. Weight at enrollment, mode of feeding, maternal PMTCT protocol, duration of ART and mode of delivery were used to find the association with unfavorable outcomes among exposed infants. [5,8,18–20] Transferred-out mothers and exposed infants were excluded from the models. Proportionality assumptions were tested using Schoenfeld residuals, log-log plots, and observed versus predicted survival plots. Statistical significance was assessed at 5% probability of type-1 error and 95% confidence intervals (95% CI) were estimated for attrition rates and hazard ratios.

Results
A total of 678 pregnant women were enrolled into the PMTCT program between March 2011 and June 2014. The median age (interquartile-range) at enrollment was 29 (26–33) years. Among these women, 19 (2.8%) were lost to follow-up before delivery, 1 (0.2%) had stillbirth and the remaining 607 (99.8%) live births. The LTFU rate among mother was 7 per 1000 person-years (PY) (95% CI 6–9). Among women who had delivery history (608), 12(2%) were dead, 81 (13%) were LTFU, 497 (82%) were transferred out to other IHC sites after delivery and 18 (3%) were on regular follow-up by 30th June 2016. Out of 607 HIV-exposed infants, 99 (16%) were lost to follow-up before the final diagnosis was made with LTFU rate of 10 per 1000 person-years (95% CI 8.52–12.9). Of 457 babies with HIV-test recorded 9 (2%) were tested HIV-positive, as shown in Fig 1.

Table 2 presents the socio-demographic and clinical characteristics of the enrolled mothers, rate of LTFU across different characteristics and their association with LTFU. Rate of LTF was highest in mothers who did not receive ART (44 LTFU in 1,000 PY follow-up) followed by option B and option A. The lowest LTFU rate was seen in mothers who received lifelong ART (4 LTFU in 1,000 PY follow-up). However, in adjusted analysis only maternal option B was found to be significantly associate with maternal LTFU (adjusted Hazard Ratio (aHR) 3.52, 95% CI 1.38–8.98).

Table 3 shows the infant and maternal socio-demographic and clinical characteristics, rate of unfavorable outcomes (HIV-positive diagnosis, LTFU and death) and their association with unfavorable outcomes of exposed babies. Rate of unfavorable outcomes was lowest in exposed infants whose mothers received longer duration of ART ≥24week before delivery (6 in 1000 PY follow up). In adjusted analysis, babies with weight <2.5 Kg at enrolment, receiving mixed-feeding, delivered by vaginal delivery and mother receiving option B PMTCT protocol were significantly associated with LTFU among exposed babies [aHR(95% CI): 5.40(1.66–17.53), 5.91(1.68–20.84), 2.27 (1.22–4.22) and 2.33 (1.16–4.69) respectively].

Discussion
This is the first study looking at the outcomes of HIV-infected mothers and their exposed infants enrolled in an integrated, hospital-based PMTCT program, in Myanmar. With a recorded mother-to-child HIV transmission risk of less than 2%, considerably lower than the 5% target set by the National AIDS Program, Myanmar. So this program could be considered successful at the national and regional level [15]. However, the high loss to follow-up observed among the pregnant women and their HIV-exposed infants highlights several programmatic challenges and requires urgent need to change in policy and practice.

The proportion of mothers who were LTFU after delivery was found to be five times higher than LTFU before delivery. There are many reasons of higher LTFU after delivery. The
HIV\textsuperscript{\textregistered}-infected pregnant mothers enrolled between March 2011 and June 2014
n=678

Mother who were:
Lost-to-follow-up, n= 19 (2.8%)
Death, n= 11 (1.6%)
Miscarriage, n= 5 (0.7%)
Transfer-out, n= 35 (5.2%)

Delivery
n= 608 (89.7%)

Stillbirth
N= 1 (0.2%)

Live Birth
Exposed babies
N= 607 (99.8%)

Not tested for HIV*
n= 6 (1.0%)

Transfer-out
n=27 (4.4%)

Lost-to-follow-up
n= 99 (16.3%)

Death
n= 18 (3.0%)

Tested for HIV
n=457 (75.3%)

Positive
n=9 (2%)

Negative
n=448 (98%)

Fig 1. Cascade of PMTCT program in Central Women Hospital, Mandalay, Myanmar. HIV; \textsuperscript{\textregistered}Human Immunodeficiency virus. *babies less than 9 months of age who were under regular follow-up and had not tested for HIV.

https://doi.org/10.1371/journal.pone.0184426.g001
Table 2. Characteristics and factors associated with loss to follow up among HIV-infected mothers enrolled in prevention of mother to child transmission program Mandalay, Myanmar, March 2011-June 2014.

| Maternal characteristics | Total n | LTFU\textsuperscript{\textregistered} n (%) | Rate in 1000 PY\textsuperscript{#} (95% CI) | Unadjusted HR\textsuperscript{Ɣ} (95% CI) | Adjusted HR\textsuperscript{Ɣ} (95% CI) |
|--------------------------|---------|-----------------------------------|--------------------------|--------------------------|--------------------------|
| Total                     | 678     | 101 (15)                          | 7 (6–9)                  |                          |                          |
| Age group                 |         |                                   |                          |                          |                          |
| 15–24                     | 123     | 20 (16)                           | 8 (5–13)                 |                          |                          |
| 25–34                     | 424     | 55 (13)                           | 6 (5–8)                  | 0.84 (0.47–1.48)         |                          |
| ≥ 35                      | 131     | 26 (20)                           | 9 (6–15)                 | 1.17 (0.6–2.27)          |                          |
| PMTCT Protocol            |         |                                   |                          |                          |                          |
| No ART                    | 60      | 28 (47)                           | 44 (28–70)               | 9.81 (5.34–18.04)\textsuperscript{**} | 5.41 (0.65–45.23)       |
| Option A                  | 136     | 22 (16)                           | 7 (4–11)                 | 1.82 (0.98–3.39)         | 1.3 (0.46–3.74)         |
| Option B                  | 108     | 24 (22)                           | 14 (9–22)                | 3.52 (1.99–6.23)\textsuperscript{**} | 3.52 (1.38–8.96)\textsuperscript{*} |
| B+/Lifelong               | 374     | 27 (7)                            | 4 (2–5)                  |                          |                          |
| CD4 before delivery (cells/mm\textsuperscript{3}) |         |                                   |                          |                          |                          |
| <350                      | 221     | 15 (7)                            | 3 (2–5)                  | 1                        |                          |
| ≥350                      | 192     | 18 (9)                            | 5 (3–7)                  | 1.7 (0.82–3.53)          | 0.99 (0.42–2.34)        |
| WHO staging (Baseline)    |         |                                   |                          |                          |                          |
| I and II                  | 550     | 89 (16)                           | 7 (6–10)                 | 2.42 (1.11–5.26)\textsuperscript{*} |                          |
| III and IV                | 118     | 9 (8)                             | 3 (1–6)                  |                          |                          |
| Missing                   | 10      | 3(0.3)                            |                          | 1                        |                          |
| Pregnancy Outcomes        |         |                                   |                          |                          |                          |
| Alive                     | 607     | 81 (13)                           | 6 (5–8)                  |                          |                          |
| Still Birth               | 1       | 0                                 | -                        |                          |                          |
| Miscarriage               | 5       | 1 (20)                            | 23 (3–165)               | 4.25 (0.59–30.77)        |                          |
| Missing                   | 65      |                                   |                          |                          |                          |
| Mode of delivery          |         |                                   |                          |                          |                          |
| VD \textsuperscript{δ}    | 129     | 26 (20)                           | 9 (6–14)                 | 1.6 (0.94–2.72)          | 0.71 (0.25–2.05)        |
| LSCS \textsuperscript{λ}  | 475     | 55 (43)                           | 5 (4–7)                  | 1                        | 1                        |
| Missing                   | 74      | 20 (27)                           |                          |                          |                          |
| Place of delivery         |         |                                   |                          |                          |                          |
| Home                      | 37      | 7 (19)                            | 10 (5–23)                | 1.69 (0.73–3.9)          |                          |
| Hospital                  | 567     | 74 (13)                           | 6 (5–8)                  |                          |                          |
| Missing                   | 74      |                                   |                          |                          |                          |
| Employment                |         |                                   |                          |                          |                          |
| No                        | 361     | 46 (13)                           | 6 (5–9)                  |                          |                          |
| Yes                       | 256     | 51 (20)                           | 9 (7–13)                 | 1.5 (0.97–2.33)          |                          |
| Missing                   | 61      |                                   |                          |                          |                          |
| Literate                  |         |                                   |                          |                          |                          |
| No                        | 38      | 8 (21)                            | 11 (5–26)                |                          |                          |
| Yes                       | 581     | 89 (15)                           | 7 (6–9)                  | 0.79 (0.32–1.95)         |                          |
| Missing                   | 59      |                                   |                          |                          |                          |

LTFU; loss to follow up
* (p value < 0.05)
** (p value < 0.001)
\textsuperscript{PMTCT, prevention of mother to child transmission}
\textsuperscript{PY, person-years}
\textsuperscript{HR, hazard ratio}
\textsuperscript{LSCS, Lower segment caesarean session}
\textsuperscript{VD, Normal vaginal delivery}

\url{https://doi.org/10.1371/journal.pone.0184426.t002}
Table 3. Characteristics and factors associated with unfavorable outcomes (HIV+ diagnosis, death and loss to follow up) among HIV-exposed babies in prevention of mother to child transmission program, Mandalay, Myanmar, March 2011-June 2014.

| Characteristics                | Total n (%) | Unfavorable Outcome n (%) | Rate in 1000 PY* (95% CI) | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|--------------------------------|-------------|----------------------------|---------------------------|------------------------|----------------------|
| Total                          | 580         | 126 (22)                   | 13 (11–16)                |                        |                      |
| Sex                            |             |                            |                           |                        |                      |
| Male                           | 304         | 53 (17)                    | 11 (8–14)                 | 0.83 (0.57–1.23)       |                      |
| Female                         | 257         | 55 (21)                    | 13 (10–17)                | 1                      |                      |
| Missing                        | 19          | 18 (95)                    |                           |                        |                      |
| Weight at enrollment (kg)      |             |                            |                           |                        |                      |
| ≤2.5                           | 11          | 7 (64)                     | 54 (24–120)               | 5.03 (2.20–11.52)**    | 5.40 (1.66–17.53)*   |
| >2.5                           | 540         | 91 (17)                    | 10 (9–13)                 | 1                      | 1                    |
| Missing                        | 29          | 28 (97)                    |                           |                        |                      |
| Feeding mode                   |             |                            |                           |                        |                      |
| Formula Feeding                | 489         | 83 (17)                    | 10 (8–12)                 | 1                      | 1                    |
| Breast Feeding                 | 71          | 32 (45)                    | 34 (24–48)                | 3.45 (2.27–5.26)**     | 1.95 (0.94–4.10)     |
| Mixed Feeding                  | 10          | 3 (30)                     | 24 (8–74)                 | 2.46 (0.77–7.83)       | 5.91 (1.68–20.84)*   |
| Missing                        | 10          | 8 (80)                     |                           |                        |                      |
| ARV prophylaxis                |             |                            |                           |                        |                      |
| AZT                           | 420         | 64 (15)                    | 9 (7–12)                  | 1                      |                      |
| NVP                           | 61          | 18 (30)                    | 20 (13–32)                | 2.24 (1.32–3.8)*       |                      |
| Missing                        | 99          | 44 (44)                    |                           |                        |                      |
| Maternal PMTCT Protocol        |             |                            |                           |                        |                      |
| No ART                         | 40          | 22 (55)                    | 51 (32–82)                | 5.64 (3.21–9.91)**     |                      |
| Option A                       | 120         | 29 (24)                    | 14 (9–20)                 | 1.49 (0.93–2.42)       | 1 (0.48–2.1)         |
| Option B                       | 97          | 25 (26)                    | 18 (12–27)                | 1.95 (1.20–3.18)*      | 2.33 (1.16–4.69)*    |
| B+/Lifelong                    | 323         | 50 (15)                    | 9 (7–12)                  | 1                      | 1                    |
| Maternal CD4 before delivery   |             |                            |                           |                        |                      |
| (Cells/mm3)                    |             |                            |                           |                        |                      |
| <350                           | 213         | 37 (17)                    | 9 (7–13)                  | 1                      |                      |
| >350                           | 178         | 24 (13)                    | 8 (5–12)                  | 0.84 (0.49–1.44)       |                      |
| Missing                        | 189         | 65 (34)                    |                           |                        |                      |
| Duration of ART before Delivery (week) |     |                            |                           |                        |                      |
| ≤12                            | 208         | 42 (20)                    | 12 (9–16)                 | 2.05 (1.07–3.93)*      | 1.68 (0.77–3.68)     |
| 12–24                          | 112         | 17 (15)                    | 8 (5–13)                  | 1.39 (0.66–2.95)       | 1.43 (0.60–3.42)     |
| >24                            | 129         | 14 (11)                    | 6 (3–10)                  | 1                      | 1                    |
| Missing                        | 131         | 53 (40)                    |                           |                        |                      |
| Maternal WHO staging (Baseline) |             |                            |                           |                        |                      |
| I and II                       | 476         | 110 (23)                   | 13 (11–17)                | 1.54 (0.88–2.70)       |                      |
| III and IV                     | 96          | 14 (15)                    | 9 (5–15)                  | 1                      |                      |
| Missing                        | 8           | 2 (25)                     |                           |                        |                      |
| Mode of delivery               |             |                            |                           |                        |                      |
| VD                             | 124         | 44 (35)                    | 25 (18–35)                | 2.49 (1.68–3.68)**     | 2.27 (1.22–4.22)*    |
| LSCS                           | 452         | 80 (18)                    | 10 (8–13)                 | 1                      | 1                    |
| Missing                        | 4           | 2 (50)                     |                           |                        |                      |
| Place of delivery              |             |                            |                           |                        |                      |
| Home                           | 36          | 15 (42)                    | 31 (18–53)                | 2.54 (1.42–4.55)*      |                      |
| Hospital                       | 540         | 109 (20)                   | 12 (10–15)                | 1                      |                      |
| Missing                        | 4           | 2 (50)                     |                           |                        |                      |

(Continued)
pregnant women have to attend ante-natal care clinics (ANC) regularly and therefore have less chance of dropping out from the PMTCT clinic during AN period which in this program is integrated into ANC and co-located in the same compound[21]. However, after delivery, mothers need to attend only one postal-natal clinic on 45th days after delivery which may or may not be the same as PMTCT clinic appointment. Therefore, this is the possible reason that mother did not attend PMTCT clinic after delivery. In addition, most working women return to work soon after delivery, making regular PMTCT follow-up challenging and competing with other life priorities.

The LTFU rate in PMTCT IHC cohort was higher than adult IHC program cohort[22]. This can lead to adverse health outcomes (higher morbidity and mortality) of mothers and their exposed babies. This is because the interruption of ART can lead to unsuccessful treatment outcomes in mother who required ART for their own health. In addition, MTCT risk can be increased if LTFU occurred before delivery as well as in breastfeeding mothers. Moreover, the exposed babies may miss the opportunity of timely diagnosis of HIV and early ART initiation if exposed babies were HIV positive. Disengagement from PMTCT program could be more likely to occur if mothers lived far from the hospital, if public transportation was not available, and if they were dealing with family and social problems: it is well documented that families affected by HIV/AIDS face several challenges from financial constrains to stigma and discrimination to loss of social resources and support[21,23,24].

In our study, pregnant women who were not on ART or were on option B PMTCT protocol were more likely to be LTFU compared to women on option B+ protocol (lifelong ART). Several different factors such as having later gestational age at ART initiation, type of PMTCT protocol (single does NVP), being newly diagnosed with HIV in the current pregnancy, stigma and discrimination, low knowledge of PMTCT program, low coverage of PMTCT programs, longer waiting time and provider clinical knowledge and attitude were associated with LTFU[9,21,24–26].

Exposed babies with body weigh less than 2.5 kg were more likely to experience unfavorable outcomes in this setting. This low weight at enrolment is associated with in utero transmission

Table 3. (Continued)

| Characteristics | Total n (%) | Unfavorable Outcome n (%) | Rate in 1000 PY* (95% CI) | Unadjusted HRγ (95% CI) | Adjusted HRγ (95% CI) |
|-----------------|------------|---------------------------|--------------------------|------------------------|------------------------|
| Employment      |            |                           |                          |                        |                        |
| No              | 314        | 67 (21)                   | 13 (10–16)               | 1                      | 1                      |
| Yes             | 217        | 54 (25)                   | 15 (12–20)               | 1.22 (0.84–1.78)       | 1                      |
| Missing         | 49         | 5 (10)                    |                          |                        |                        |
| Literate        |            |                           |                          |                        |                        |
| No              | 31         | 8 (26)                    | 19 (9–38)                | 1                      | 1                      |
| Yes             | 501        | 113 (23)                  | 14 (11–16)               | 0.73 (0.35–1.49)       | 1                      |
| Missing         | 48         | 5 (10)                    |                          |                        |                        |

* (p value < 0.05)  
** (p value < 0.001), HIV; Human Immunodeficiency Virus  
*PY, person-years  
γHR, hazard ratio  
AZT, Zidovudine  
NVP, Nevirapine  
VD, Normal vaginal delivery  
LSCS, Lower segment caesarean session  

https://doi.org/10.1371/journal.pone.0184426.t003
and pre-term delivery. In addition, vaginal delivery and mixed infant feeding were found significantly associated with unfavorable outcomes among exposed babies in this cohort; these factors were previously shown to be associated with such outcomes in other studies[8,18,27]. Exposed babies born to mothers who received no ART or received option A and B protocol were also more likely to have unfavorable outcomes; as ART was discontinued one week after breastfeeding cessation, we hypothesize that the mothers were less motivated to attend the clinic regularly and she also failed to come clinic for her exposed babies.

This study has several strengths. First, the routinely collected program data was used which reflect the real situation in the field; therefore the findings could give reasonable and programmatic feedback to the program. Secondly, the sample size in this study was relatively large as well as the completeness and robustness of the data compared to other PMTCT program descriptions in other countries[8,28–30]. Lastly, we strictly adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines in conducting and reporting the study[31].

The study did not come without certain limitations. Since this study used routinely collected data from an ongoing program, a certain amount of missing values were found and excluded from the analysis. Further strengthening of the monitoring and evaluation and reporting and recording systems is recommended. The reasons behind the LTFU of this programmatic cohort have not been explored in this study; further quantitative and qualitative studies were planned to conduct in order to address this most challenging programmatic outcome. Furthermore, the linkage between the antenatal HIV testing facility and PMTCT services were not looked at in this study where Lost to follow up was occurred up to 49% in low and middle income countries [26]. Lastly, some factors associated with LTFU of mothers and outcomes of exposed infants, variables found to be significant in unadjusted analysis did not hold when adjusted models were fit. The main reason for this could be the lack of statistical power.

**Conclusion**

A low mother-to-child HIV transmission rate has been recorded in a public hospital-based program in Mandalay, Myanmar, which indicates a successful PMTCT intervention. There are several factors currently adopted in this setting such as integrated PMTCT care, counselling, LTFU tracing, provision of formula feeding and one stop services for both mothers and babies until confirmed HIV diagnosed of exposed babies, might have contributed to the overall success of this intervention, as evidenced by the low mother to child HIV transmission rate reported. According to the evidence produced by this study, we recommend that elements of the comprehensive package of this PMTCT program might be considered to be adopted by the National AIDS Program and expanded to other part of the country. However, high LTFU of HIV-infected mothers and exposed babies was also recorded. Lessons learned from this program could be used to inform policy and practice in the whole country, while the programmatic challenge of LTFU should be urgently addressed.

**Supporting information**

S1 Table. Characteristics and factors associated with three separate outcomes (HIV+ diagnosis, death and loss to follow up) among HIV-exposed babies in prevention of mother to child transmission program, Mandalay, Myanmar, March 2011-June 2014. * (p value < 0.05), HR, hazard ratio; YAZT, Zidovudine; NVP, Nevirapine; VD, Normal vaginal delivery; LSCS, Lower segment caesarean session. (DOCX)
S1 File. Dataset for study on low mother-to-child HIV transmission rate but high loss-to-follow-up among mothers and babies in Mandalay, Myanmar; a cohort study.
(DTA)

Acknowledgments

We gratefully acknowledge the support of National AIDS program (NAP), Medical Superintendent Professor and Head of Obstetrics and Gynecology Department of Central Women Hospital, HIV unit (The Union), PLHIV network and all PLHIV and exposed babies included in this study. This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Program for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The model is based on a course developed jointly by the International Union Against Tuberculosis and Lung Disease (The Union) and Médecins sans Frontières (MSF/Doctors Without Borders). The specific SORT IT program which resulted in this publication was jointly developed and implemented by: The Union South-East Asia Office, New Delhi, India; the Centre for Operational Research, The Union, Paris, France; The Union, Mandalay, Myanmar; the Operational Research Unit (LUXOR), MSF Brussels Operational Center, Luxembourg; Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India; Department of Community Medicine, Government T.D Medical College, Alappuzha, India; College of Life and Environmental Sciences, Exeter University, UK; Velammal Medical College Hospital & Research Institute, Madurai, India; and Institute of Medicine, University of Chester, UK.

Author Contributions

Conceptualization: Myo Minn Oo, Nang Thu Thu Kyaw, Petros Isaakidis.
Data curation: Khine Wut Yee Kyaw, Khaing Hnin Phyo, Petros Isaakidis.
Formal analysis: Khine Wut Yee Kyaw, Myo Minn Oo, Nang Thu Thu Kyaw, Petros Isaakidis.
Investigation: Khine Wut Yee Kyaw, Nang Thu Thu Kyaw.
Methodology: Khine Wut Yee Kyaw, Myo Minn Oo, Nang Thu Thu Kyaw, Khaing Hnin Phyo, Petros Isaakidis.
Project administration: Khine Wut Yee Kyaw.
Resources: Myo Minn Oo, Nang Thu Thu Kyaw, Petros Isaakidis.
Supervision: Khine Wut Yee Kyaw, Nang Thu Thu Kyaw, Petros Isaakidis.
Validation: Khine Wut Yee Kyaw, Myo Minn Oo, Petros Isaakidis.
Visualization: Khine Wut Yee Kyaw, Myo Minn Oo, Nang Thu Thu Kyaw, Petros Isaakidis.
Writing – original draft: Khine Wut Yee Kyaw, Myo Minn Oo, Nang Thu Thu Kyaw, Khaing Hnin Phyo, Theingi Mya, Nilar Aung, Htun Nyunt Oo, Petros Isaakidis.
Writing – review & editing: Khine Wut Yee Kyaw, Myo Minn Oo, Nang Thu Thu Kyaw, Khaing Hnin Phyo, Thet Ko Aung, Theingi Mya, Nilar Aung, Htun Nyunt Oo, Petros Isaakidis.
References

1. UNAIDS. GAP Reprt 2016. 2016.
2. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization. 2013. 978 9 2 4 1505727
3. World Health Organization (WHO). Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. World Health Organization; 2010. https://doi.org/10.1162/LEON_r_00464
4. Kristine SF, Samooel FC, Gautney BJ, Okoth V, Goggin K, Study H. Progress Toward Eliminating Mother to Child Transmission of HIV in Kenya: Review of Treatment Guideline Uptake and Pediatric Transmission at Four Government Hospitals Between 2010 and 2012. AIDS Behav. Springer US; 2016; 2602–2611. https://doi.org/10.1007/s10461-015-1071-5 PMID: 25903508
5. Nduati EW, Hassan AS, Knight MG, Muema DM, Jahangir MN, Mwaranga SL, et al. Outcomes of prevention of mother to child transmission of the human immunodeficiency virus-1 in rural Kenya-a cohort study. BMC Public Health. BMC Public Health; 2015; 15: 1008. https://doi.org/10.1186/s12889-015-2355-4 PMID: 26433396
6. Thomas TK, Masaba R, Borkowf CB, Ndibo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011; 8: e1001015. https://doi.org/10.1371/journal.pmed.1001015 PMID: 21468300
7. Js R, Mi N. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1 (Review). 2007; 1.
8. Landers DV, Duarte G. Mode of delivery and the risk of vertical transmission of HIV-1. N Engl J Med. 1999; 341: 205; author reply 206–7.
9. Kalembo FW, Zgambo M, Du YK. Progress of mother-to-child transmission of HIV programs in China: Successes, challenges and way forward. Chin Med J (Engl). 2013; 126: 3172–3176. https://doi.org/10. 3760/cma.j.issn.0366-6999.20123475
10. UNAIDS. Gap Report 2014. Steitzerland; 2014.
11. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. UNAIDS. 2014.
12. National AIDS Program. Global AIDS Response Progress Report Myanmar 2015. 2015.
13. National AIDS Program. Global AIDS Response Progress Report Myanmar 2014. 2014.
14. UNAIDS. HIV in Asia and the Pacific. UNAIDS. 2013. 10.1017/CBO9781107415324.004
15. National AIDS Program. National Strategic Plan on HIV and AIDS Myanmar (2016–2020). National AIDS Program; 2015.
16. World Health Organization (WHO). Myanmar:WHO statistical profile. 2013.
17. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - 2nd ed. World Heal Organ. 2016; 480.
18. Anoje C, Aiyenigba B, Suzuki C, Badru T, Akpoigbe K, Odo M, et al. Reducing mother-to-child transmission of HIV: findings from an early infant diagnosis program in south-south region of Nigeria. BMC Public Health. 2012; 12: 184. https://doi.org/10.1186/1471-2458-12-184 PMID: 22410161
19. Chintu N, Mulindwa J, Benjamin J, Chi BH, Stringer JSA. Optimal Time on HAART for Prevention of Motherto-Child Transmiss ion of HIV. NIH Public Access. 2013; 58: 224–228. https://doi.org/10.1097/QAI.0b013e318229147e Optimal
20. Giuliano M, Andreotti M, Liotta G, Jere H, Sagno JB, Maulidi M, et al. Maternal Antiretroviral Therapy for the Prevention of Mother-To-Child Transmission of HIV in Malawi: Maternal and Infant Outcomes Two Years after Delivery. PLoS One. 2013; 8: 4–13. https://doi.org/10.1371/journal.pone.0068950 PMID: 23894379
21. Iroezi ND, Mindry D, Kawale P, Chikowi G, Jansen PA, Hoffman RM. A qualitative analysis of the barriers and facilitators to receiving care in a prevention of mother-to-child program in Nkhoma, Malawi. Afr J Reprod Health. 2013; 17: 118–29.
22. Thida A, Tun STT, Zaw SKK, Lover AA, Cavailler P, Chunn J, et al. Retention and risk factors for attrition in a large public health ART program in myanmar: A retrospective cohort analysis. PLoS One. 2014; 9. https://doi.org/10.1371/journal.pone.0106815 PMID: 25268903
23. Duff P, Kipp W, Wild TC, Rubaale T, Oketch-Ojony J. Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc. 2010; 13: 37. https://doi.org/10.1186/1758-2652-13-37 PMID: 20863399
24. Geldsetzer P, Yapa HMN, Vaikath M, Oggbuji O, Fox MP, Essajee SM, et al. A systematic review of interventions to improve postpartum retention of women in PMTCT and ART care. J Int AIDS Soc. 2016; 19. https://doi.org/10.7448/IAS.19.1.20679 PMID: 27118443

25. Phillips T, Thebus E, Bekker L-G, McIntyre J, Abrams EJ, Myer L. Disengagement of HIV-positive pregnant and postpartum women from antiretroviral therapy services: a cohort study. J Int AIDS Soc. 2014; 17: 19242. https://doi.org/10.7448/IAS.17.1.19242 PMID: 25301494

26. Sibanda EL, Weller IVD, Hakim JG, Cowan FM. The magnitude of loss to follow-up of HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum of care: a systematic review and meta-analysis. AIDS. 2013; 27: 2787–2797. https://doi.org/10.1097/QAD.000000000000027 PMID: 24056068

27. Noubiap JJN, Bongoe A, Demanou SA. Mother-to-child transmission of HIV: findings from an early infant diagnosis program in Bertoua, Eastern Cameroon. Pan Afr Med J. 2013; 15: 65. https://doi.org/10.11604/pamj.2013.15.65.2551 PMID: 24198870

28. Altan AMD, Taafo F, Fopa F, Buonomo E, Marazzi MC, Nielsen-Saines K, et al. An assessment of option b implementation for the prevention of mother to child transmission in dschang, cameroon: Results from the dream (drug resource enhancement against aids and malnutrition) cohort. Pan Afr Med J. 2016; 23: 1–9. https://doi.org/10.11604/pamj.2016.23.1.8442

29. Chetty T, Knight S, Giddy J, Crankshaw TL, Butler L, Newell M-L. A retrospective study of Human Immunodeficiency Virus transmission, mortality and loss to follow-up among infants in the first 18 months of life in a prevention of mother-to-child transmission programme in an urban hospital in Kwa-Zulu-Natal, South Africa. BMC Pediatr. 2012; 12: 146. https://doi.org/10.1186/1471-2431-12-146 PMID: 22963527

30. Zhou Z, Meyers K, Li X, Chen Q, Qian H, Lao Y, et al. Prevention of mother-to-child transmission of HIV-1 using highly active antiretroviral therapy in rural Yunnan, China. J Acquir Immune Defic Syndr. 2010; 53: S15–S22. https://doi.org/10.1097/QAI.0b013e3181c7d47b PMID: 20104104

31. von Elm E, Altman DG, Egger MS, P. Gøtzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61: 344–349. https://doi.org/10.1016/j.jclinepi.2007.11.008 PMID: 18313558